文献速递核素与放射性配体治疗甲状腺核医学骨显像与常规 SPECT

镭-223治疗碘难治性分化型甲状腺癌骨转移的II期RADTHYR试验

RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-02-23

RADTHYR是一项多中心单臂Simon两阶段II期试验,评估α发射体镭-223在放射性碘难治性分化型甲状腺癌骨转移患者中的疗效。主要终点为三次55 kBq/kg给药后按PERCIST标准18F-FDG PET/CT评估的疗效。因中期分析显示骨转移无应答,试验提前终止,并观察到严重血液学毒性。

要点

  • 三次镭-223后18F-FDG PET/CT示4/10稳定、6/10进展;六次后4/10稳定、5/10进展、1/10不可评估。
  • 六次后99mTc-HMDP骨扫描9例稳定、1例不可评估;18FNa PET/CT 8例稳定、1例部分缓解、1例不可评估。
  • 3例患者在末次给药后发生急性髓系白血病、早幼粒细胞白血病和慢性髓系白血病,被认为与药物相关。

核心结论

  • 中期分析因RAIR甲状腺癌骨转移对镭-223缺乏应答而终止试验。
  • 在重度经RAI和体外放疗预处理的患者中观察到严重血液学毒性。

研究设计与样本

  • RADTHYR为多中心、单臂、前瞻性Simon两阶段II期试验(NCT02390934)。
  • 2015年7月至2017年12月共入组10例患者(4例男性;中位年龄74岁)。
  • 主要目标为确立三次55 kBq/kg镭-223给药后按PERCIST标准18F-FDG PET/CT评估的疗效。

主要发现

  • 镭-223给药前,患者接受的中位RAI累积活度为15 GBq(7.4-35.6),9例接受体外放疗、8例骨手术、5例骨水泥成形、2例冷冻消融。
  • 三次给药后18F-FDG PET/CT示4/10稳定、6/10进展;六次后示4/10稳定、5/10进展、1/10不可评估。
  • 六次注射后99mTc-HMDP骨扫描示9例稳定、1例不可评估;18FNa PET/CT示8例稳定、1例部分缓解、1例不可评估。
  • 研究期间未报告显著临床获益;6例患者发生骨骼事件,无骨骼事件中位时间为12.1个月。

关键数值与推荐

  • 镭-223给药方案为每次55 kBq/kg,主要终点评估三次给药后疗效,次要终点评估六次给药后疗效。
  • 疗效评估采用PERCIST标准(18F-FDG PET/CT),并辅以99mTc-HMDP骨扫描和18FNa PET/CT。

临床怎么用

  • 对于重度经RAI和体外放疗预处理的RAIR甲状腺癌骨转移患者,镭-223未显示骨转移应答且存在严重血液学毒性风险。

局限性

  • 试验为单臂设计且因中期分析提前终止,样本量仅10例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This is the first prospective trial evaluating the efficacy of alpha emitter Radium-223 in patients with bone metastases from radioactive iodine (RAI) refractory (RAIR) differentiated thyroid cancer. METHODS: RADTHYR is a multicenter, single-arm prospective Simon two-stage phase II trial (NCT02390934). The primary objective was to establish the efficacy of three administrations of 55 kBq/kg of Radium-223 by 18F-FDG PET/CT according to PERCIST criteria. Secondary objectives were to establish the efficacy of six administrations of Radium-223 by 18F-FDG PET/CT, 99mTc-HMDP bone scan and 18FNa PET/CT, clinical benefits, changes in serum bone markers, thyroglobulin levels, and safety. RESULTS: Ten patients were enrolled between July 2015 and December 2017 (4 M; median age 74 years). Prior to Radium-223 administration, patients received a median RAI cumulative activity of 15 GBq (7.4-35.6), external radiation therapy (n = 9), bone surgery (n = 8), cimentoplasty (n = 5), and cryoablation (n = 2). 18F-FDG PET/CT showed stable disease (SD) in 4/10 and progressive disease (PD) in 6/10 cases after three administrations and SD in 4/10, PD in 5/10 cases, and 1/10 non-evaluable (NE) case after six administrations. After six injections, 99mTc-HMDP bone scan showed SD in 9 cases and was NE in 1 case; 18FNa PET/CT showed SD in 8 cases, partial response (PR) in 1 case, and was NE in 1 case. No significant clinical benefits were reported during the study. A skeletal event occurred in 6 patients (median time without skeletal event of 12.1 months). Seventy-seven adverse events were reported during treatment (7 of grade 3-4). Three patients developed an acute myeloid, a promyelocytic, and a chronic myeloid leukemia after the last Radium-223 administration considered as drug-related. CONCLUSION: The trial was stopped after interim analysis for lack of response of bone metastases from RAIR thyroid cancer to Radium-223. Severe hematological toxicity was observed in patients heavily pretreated with RAI and external radiation. TRIAL REGISTRATION NUMBER: NCT02390934. Registration date 18.03.2015.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Deandreis D, Maillard A, Zerdoud S, et al. RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 33619600. doi:10.1007/s00259-021-05229-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。